Living-donor liver transplantation and hepatitis C

HPB Surgery

Volumn 2013, Issue , 2013, Pages

  Akamatsu, Nobuhisa ^a,b   Sugawara, Yasuhiko ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874529088     PISSN: 08948569     EISSN: 16078462     Source Type: Journal    
DOI: 10.1155/2013/985972     Document Type: Review

References (209)

1. Strong R. W., Lynch S. V., Ong T. H., Matsunami H., Koido Y., Balderson G. A., Successful liver transplantation from a living donor to her son. New England Journal of Medicine 1990 322 21 1505 1507 2-s2.0-0025333264 (Pubitemid 20179865)
2. Hashikura Y., Makuuchi M., Kawasaki S., Matsunami H., Ikegami T., Nakazawa Y., Kiyosawa K., Ichida T., Successful living-related partial liver transplantation to an adult patient. Lancet 1994 343 8907 1233 1234 2-s2.0-0028329101 (Pubitemid 24147586)
3. Sugawara Y., Makuuchi M., Advances in adult living donor liver transplantation: a review based on reports from the 10th anniversary of the adult-to-adult living donor liver transplantation meeting in Tokyo. Liver Transplantation 2004 10 6 715 720 2-s2.0-2942704043 10.1002/lt.20179 (Pubitemid 38787127)
4. Merion R. M., Current status and future of liver transplantation. Seminars in Liver Disease 2010 30 4 411 421 2-s2.0-77958155198 10.1055/s-0030-1267541
5. Adam R., McMaster P., O'Grady J. G., Castaing D., Klempnauer J. L., Jamieson N., Neuhaus P., Lerut J., Salizzoni M., Pollard S., Muhlbacher F., Rogiers X., Garcia Valdecasas J. C., Berenguer J., Jaeck D., Moreno Gonzalez E., Evolution of liver transplantation in Europe: report of the European liver transplant registry. Liver Transplantation 2003 9 12 1231 1243 2-s2.0-10744232496 10.1016/j.lts.2003.09.018 (Pubitemid 37536793)
6. Wiesner R. H., Sorrell M., Villamil F., Balan V., Berenguer M., Brown R. S., Charlton M. R., Davis G. I., Dickson R. C., Everson G. T., Freeman R. B., Gane E. J., Ghobrial R. M., Gordon F., Kuo P., Lake J. R., Marcos A., Mason A., McCashland T., McCaughan G. W., Miller C., Neuberger J., Neuhaus P., Poterucha J. J., Rakela J. L., Rodes J., Rosen H. R., Schiff E. R., Shaw B. W., Shiffman M. L., Terrault N., Trotter J., Vierling J. M., Wall W. J., Wright T. L., Report of the first international liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transplantation 2003 9 11 S1 S9 2-s2.0-10744233398 10.1053/jlts.2003.50268 (Pubitemid 37407996)
7. Sugawara Y., Makuuchi M., Living donor liver transplantation to patients with hepatitis C virus cirrhosis. World Journal of Gastroenterology 2006 12 28 4461 4465 2-s2.0-33747508125 (Pubitemid 44256330)
8. Berenguer M., Charco R., Pascasio J. M., Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. Liver International 2012 32 5 712 713 10.1111/j.1478-3231.2011. 02731.x
9. Garcia-Retortillo M., Forns X., Feliu A., Moitinho E., Costa J., Navasa M., Rimola A., Rodes J., Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002 35 3 680 687 2-s2.0-0036189531 10.1053/jhep.2002.31773 (Pubitemid 34183974)
10. Gane E. J., Portmann B. G., Naoumov N. V., Smith H. M., Underhill J. A., Donaldson P. T., Maertens G., Willlams R., Long-term outcome of hepatitis C infection after liver transplantation. New England Journal of Medicine 1996 334 13 815 820 2-s2.0-0029914375 10.1056/NEJM199603283341302 (Pubitemid 26099603)
11. Berenguer M., Prieto M., Rayón J. M., Mora J., Pastor M., Ortiz V., Carrasco D., San Juan F., Burgueño M. D. J., Mir J., Berenguer J., Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000 32 4, part 1 852 858 2-s2.0-0033807694
12. Narang T. K., Ahrens W., Russo M. W., Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transplantation 2010 16 11 1228 1235 2-s2.0-78349267619 10.1002/lt.22175
13. Roche B., Samuel D., Risk factors for hepatitis C recurrence after liver transplantation. Journal of Viral Hepatitis 2007 14 1 89 96 2-s2.0-35448971041 10.1111/j.1365-2893.2007.00920.x (Pubitemid 47624117)
14. Forman L. M., Lewis J. D., Berlin J. A., Feldman H. I., Lucey M. R., The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002 122 4 889 896 2-s2.0-0036207348 (Pubitemid 34267271)
15. Ghabril M., Dickson R., Wiesner R., Improving outcomes of liver retransplantation: an analysis of trends and the impact of hepatitis C infection. American Journal of Transplantation 2008 8 2 404 411 2-s2.0-38149041985 10.1111/j.1600-6143.2007.02082.x
16. Berenguer M., Natural history of recurrent hepatitis C. Liver Transplantation 2002 8 10, supplement 1 S14 S18 2-s2.0-0036793302 10.1053/jlts.2002.35781 (Pubitemid 35154038)
17. Berenguer M., Prieto M., Juan F. S., Rayón J. M., Martinez F., Carrasco D., Moya A., Orbis F., Mir J., Berenguer J., Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002 36 1 202 210 2-s2.0-18444415726 10.1053/jhep.2002. 33993 (Pubitemid 34700779)
18. Rubin A., Aguilera V., Berenguer M., Liver transplantation and hepatitis C. Clinics and Research in Hepatology and Gastroenterology 2011 35 12 805 812
19. Thuluvath P. J., Krok K. L., Segev D. L., Yoo H. Y., Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transplantation 2007 13 5 719 724 2-s2.0-34249019659 10.1002/lt.21123 (Pubitemid 46804363)
20. Belli L. S., Burroughs A. K., Burra P., Alberti A. B., Samonakis D., Cammà C., de Carlis L., Minola E., Quaglia A., Zavaglia C., Vangeli M., Patch D., Dhillon A., Cillo U., Guido M., Fagiuoli S., Giacomoni A., Slim O. A., Airoldi A., Boninsegna S., Davidson B. R., Rolles K., Pinzello G., Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transplantation 2007 13 5 733 740 2-s2.0-34249049803 10.1002/lt.21093 (Pubitemid 46796545)
21. Berenguer M., Ferrell L., Watson J., Prieto M., Kim M., Rayón M., Córdoba J., Herola A., Ascher N., Mir J., Berenguer J., Wright T. L., HCV-related fibrosis progression following liver transplantation: increase in recent years. Journal of Hepatology 2000 32 4 673 684 2-s2.0-0034070192 10.1016/S0168-8278(00)80231-7 (Pubitemid 30180389)
22. Samuel D., Forns X., Berenguer M., Trautwein C., Burroughs A., Rizzetto M., Trepo C., Report of the monothematic EASL conference on liver transplantation for viral hepatitis. Journal of Hepatology 2006 45 1 127 143 2-s2.0-33744903681 10.1016/j.jhep.2006.05.001 (Pubitemid 43850627)
23. Olthoff K. M., Abecassis M. M., Emond J. C., Kam I., Merion R. M., Gillespie B. W., Tong L., Outcomes of adult living donor liver transplantation: comparison of the adult-to-adult living donor liver transplantation cohort study and the national experience. Liver Transplantation 2011 17 7 789 797 2-s2.0-79959845523 10.1002/lt.22288
24. The Japanese Liver Transplantation Society, Liver transplantation in Japan. Registry by the Japanese liver transplantation society. Japanese Journal of Transplantation 2011 46 6 524 536
25. Ghany M. G., Strader D. B., Thomas D. L., Seeff L. B., Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009 49 4 1335 1374 2-s2.0-65449136656 10.1002/hep.22759
26. Vagefi P. A., Ascher N. L., Freise C. E., Use of living donor liver transplantation varies with the availability of deceased donor liver transplantation. Liver Transplantation 2012 18 2 160 165
27. Gane E. J., Naoumov N. V., Qian K. P., Mondelli M. U., Maertens G., Portmann B. C., Lau J. Y. N., Williams R., A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996 110 1 167 177 2-s2.0-0030045971 10.1053/gast.1996.v110.pm8536853 (Pubitemid 26021616)
28. Sreekumar R., Gonzalez-Koch A., Maor-Kendler Y., Batts K., Moreno-Luna L., Poterucha J., Burgart L., Wiesner R., Kremers W., Rosen C., Charlton M. R., Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000 32 5 1125 1130 2-s2.0-0033755058
29. Hanouneh I. A., Feldstein A. E., McCullough A. J., Miller C., Aucejo F., Yerian L., Lopez R., Zein N. N., The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transplantation 2008 14 9 1287 1293 2-s2.0-51349121640 10.1002/lt.21524
30. Papatheodoridis G. V., Barton S. G., Andrew D., Clewley G., Davies S., Dhillon A. P., Dusheiko G., Davidson B., Rolles K., Burroughs A. K., Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. Gut 1999 45 3 427 434 2-s2.0-0032795779 (Pubitemid 29400722)
31. Shackel N. A., Jamias J., Rahman W., Prakoso E., Strasser S. I., Koorey D. J., Crawford M. D., Verran D. J., Gallagher J., McCaughan G. W., Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transplantation 2009 15 7 709 718 2-s2.0-68349128254 10.1002/lt.21747
32. Feray C., Caccamo L., Alexander G. J., European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European concerted action on viral hepatitis (EUROHEP) group. Gastroenterology 1999 117 3 619 625 (Pubitemid 29409247)
33. Vargas H. E., Laskus T., Wang L. F., Radkowski M., Poutous A., Lee R., Demetris J. A., Gayowski T., Marino I. R., Singh N., Dodson F., Casavilla A., Fung J. J., Rakela J., The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transplantation and Surgery 1998 4 1 22 27 2-s2.0-0031982849 (Pubitemid 28053307)
34. Berenguer M., Crippin J., Gish R., Bass N., Bostrom A., Netto G., Alonzo J., Garcia-Kennedy R., Rayón J. M., Wright T. L., A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003 38 1 34 41 2-s2.0-0037785064 10.1053/jhep.2003.50278 (Pubitemid 36775793)
35. Selzner N., Renner E. L., Selzner M., Adeyi O., Kashfi A., Therapondos G., Girgrah N., Herath C., Levy G. A., Lilly L., Antiviral treatment of recurrent Hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009 88 10 1214 1221 2-s2.0-73849094005 10.1097/TP.0b013e3181bd783c
36. Féray C., Gigou M., Samuel D., Paradis V., Mishiro S., Maertens G., Reynés M., Okamoto H., Bismuth H., Bréchot C., Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995 108 4 1088 1096 2-s2.0-0028903851 10.1016/0016-5085(95)90207-4
37. Maluf D. G., Edwards E. B., Stravitz R. T., Kauftman H. M., Impact of the donor risk index on the outcome of hepatitis C virus-positive Liver transplant recipients. Liver Transplantation 2009 15 6 592 599 2-s2.0-68349150491 10.1002/lt.21699
38. Rifai K., Sebagh M., Karam V., Saliba F., Azoulay D., Adam R., Castaing D., Bismuth H., Reynès M., Samuel D., Féray C., Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. Journal of Hepatology 2004 41 3 446 453 2-s2.0-4344677918 10.1016/j.jhep.2004.05.013 (Pubitemid 39158754)
39. Gallegos-Orozco J. F., Yosephy A., Noble B., Aqel B. A., Byrne T. J., Carey E. J., Douglas D. D., Mulligan D., Moss A., de Petris G., Williams J. W., Rakela J., Vargas H. E., Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transplantation 2009 15 12 1872 1881 2-s2.0-71249122708 10.1002/lt.21954
40. Khapra A. P., Agarwal K., Fiel M. I., Kontorinis N., Hossain S., Emre S., Schiano T. D., Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transplantation 2006 12 10 1496 1503 2-s2.0-33750129323 10.1002/lt.20849 (Pubitemid 44594280)
41. Rayhill S. C., Wu Y. M., Katz D. A., Voigt M. D., LaBrecque D. R., Kirby P. A., Mitros F. A., Kalil R. S., Miller R. A., Stolpen A. H., Schmidt W. N., Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007 84 3 331 339 2-s2.0-34547888702 10.1097/01.tp.0000270313.31328.63 (Pubitemid 47258320)
42. Machicao V. I., Bonatti H., Krishna M., Aqel B. A., Lukens F. J., Nguyen J. H., Rosser B. G., Satyanarayana R., Grewal H. P., Hewitt W. R., Harnois D. M., Crook J. E., Steers J. L., Dickson R. C., Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004 77 1 84 92 2-s2.0-9144258432 10.1097/01.TP.0000095896. 07048.BB (Pubitemid 38116877)
43. Avolio A. W., Cillo U., Salizzoni M., Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients. American Journal of Transplantation 2011 11 12 2724 2736
44. Selzner M., Kashfi A., Selzner N., McCluskey S., Greig P. D., Cattral M. S., Levy G. A., Lilly L., Renner E. L., Therapondos G., Adcock L. E., Grant D. R., McGilvray I. D., Recipient age affects long-term outcome and hepatitis C recurrence in old donor livers following transplantation. Liver Transplantation 2009 15 10 1288 1295 2-s2.0-70350556841 10.1002/lt.21828
45. Pang P. S., Kamal A., Glenn J. S., The effect of donor race on the survival of black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transplantation 2009 15 9 1126 1132 2-s2.0-70350547564 10.1002/lt.21835
46. Saxena V., Lai J. C., 'Leary J. G. O., Donor-recipient race mismatch in African-American ant patients with chronic hepatitis C. Liver Transplantation 2012 18 5 524 531 10.1002/lt.22461
47. Walter T., Dumortier J., Guillaud O., Hervieu V., Scoazec J. Y., Boillot O., Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center. Liver Transplantation 2007 13 2 294 301 2-s2.0-33847653674 10.1002/lt.21000 (Pubitemid 46351657)
48. Lai J. C., Verna E. C., Brown R. S., O'Leary J. G., Trotter J. F., Forman L. M., Duman J. D., Foster R. G., Stravitz R. T., Terrault N. A., Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 2011 54 2 418 424 2-s2.0-79960714300 10.1002/hep.24390
49. Charlton M. R., Thompson A., Veldt B. J., Watt K., Tillmann H., Poterucha J. J., Heimbach J. K., Goldstein D., Mchutchison J., Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011 53 1 317 324 2-s2.0-78751505015 10.1002/hep.24074
50. Northup P. G., Argo C. K., Nguyen D. T., McBride M. A., Kumer S. C., Schmitt T. M., Pruett T. L., Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a us national transplant registry analysis. Transplant International 2010 23 10 1038 1044 2-s2.0-77956320554 10.1111/j.1432-2277.2010.01092.x
51. Arenas J. I., Vargas H. E., Rakela J., The use of hepatitis C-infected grafts in liver transplantation. Liver Transplantation 2003 9 11 S48 S51 2-s2.0-0242624532 10.1053/jlts.2003.50252 (Pubitemid 37408003)
52. Ballarin R., Cucchetti A., Spaggiari M., Montalti R., Di Benedetto F., Nadalin S., Troisi R. I., Valmasoni M., Longo C., de Ruvo N., Cautero N., Cillo U., Pinna A. D., Burra P., Gerunda G. E., Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation 2011 91 11 1265 1272 2-s2.0-79958290597 10.1097/TP.0b013e318219eb8f
53. Burr A. T., Li Y., Tseng J. F., Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World Journal of Surgery 2011 35 7 1590 1595
54. Watt K. D. S., Lyden E. R., Gulizia J. M., McCashland T. M., Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transplantation 2006 12 1 134 139 2-s2.0-33645101411 10.1002/lt.20583
55. Baron P. W., Sindram D., Higdon D., Howell D. N., Gottfried M. R., Tuttle-Newhall J. E., Clavien P. A., Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transplantation 2000 6 4 407 412 2-s2.0-0033942812 (Pubitemid 30489111)
56. Brandman D., Pingitore A., Lai J. C., Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transplantation 2011 17 12 1380 1386
57. Subramanian V., Seetharam A. B., Vachharajani N., Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation 2011 92 11 1259 1268
58. Lake J. R., The role of immunosuppression in recurrence of hepatitis C. Liver Transplantation 2003 9 11 S63 S66 2-s2.0-0242624528 10.1053/jlts.2003. 50264 (Pubitemid 37408006)
59. Sheiner P. A., Schwartz M. E., Mor E., Schluger L. K., Theise N., Kishikawa K., Kolesnikov V., Bodenheimer H., Emre S., Miller C. M., Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995 21 1 30 34 2-s2.0-0028891442
60. Berenguer M., Aguilera V., Prieto M., San Juan F., Rayón J. M., Benlloch S., Berenguer J., Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. Journal of Hepatology 2006 44 4 717 722 2-s2.0-33644889956 10.1016/j.jhep.2006.01.005
61. Brillanti S., Vivarelli M., de Ruvo N., Aden A. A., Camaggi V., D'Errico A., Furlini G., Bellusci R., Roda E., Cavallari A., Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transplantation 2002 8 10 884 888 2-s2.0-0036793246 10.1053/jlts.2002. 34640 (Pubitemid 35154016)
62. Vivarelli M., Burra P., Barba G. L., Canova D., Senzolo M., Cucchetti A., D'Errico A., Guido M., Merenda R., Neri D., Zanello M., Giannini F. M., Grazi G. L., Cillo U., Pinna A. D., Influence of steroids on HCV recurrence after liver transplantation: a prospective study. Journal of Hepatology 2007 47 6 793 798 2-s2.0-35748938770 10.1016/j.jhep.2007.07.023 (Pubitemid 350051119)
63. Klintmalm G. B., Davis G. L., Teperman L., A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transplantation 2011 17 12 1394 1403
64. Sgourakis G., Radtke A., Fouzas I., Mylona S., Goumas K., Gockel I., Lang H., Karaliotas C., Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transplant International 2009 22 9 892 905 2-s2.0-68849100098 10.1111/j.1432-2277.2009. 00893.x
65. Margarit C., Bilbao I., Castells L., Lopez I., Pou L., Allende E., Escartin A., A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transplant International 2005 18 12 1336 1345 2-s2.0-28444497445 10.1111/j.1432-2277.2005.00217.x (Pubitemid 41726729)
66. Kato T., Gaynor J. J., Yoshida H., Montalvano M., Takahashi H., Pyrsopoulos N., Nishida S., Moon J., Selvaggi G., Levi D., Ruiz P., Schiff E., Tzakis A., Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007 84 7 829 835 2-s2.0-38449112478 10.1097/01.tp.0000282914.20578.7b (Pubitemid 351338942)
67. Lladó L., Fabregat J., Castellote J., Ramos E., Xiol X., Torras J., Serrano T., Baliellas C., Figueras J., Garcia-Gil A., Rafecas A., Gonzalez-Pinto I., Herrero J. I., Blesa C., Rincón D., Valdivieso A., Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transplantation 2008 14 12 1752 1760 2-s2.0-58249093632 10.1002/lt.21629
68. Manousou P., Samonakis D., Cholongitas E., Patch D., O'Beirne J., Dhillon A. P., Rolles K., McCormick A., Hayes P., Burroughs A. K., Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transplantation 2009 15 12 1783 1791 2-s2.0-71249159640 10.1002/lt.21907
69. Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 2011 92 3 334 340 2-s2.0-79961028119 10.1097/TP.0b013e318223d836
70. Martin P., Busuttil R. W., Goldstein R. M., Crippin J. S., Klintmalm G. B., Fitzsimmons W. E., Uleman C., Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transplantation 2004 10 10 1258 1262 2-s2.0-6444243485 10.1002/lt.20222 (Pubitemid 39406080)
71. O'Grady J. G., Hardy P., Burroughs A. K., Elbourne D., Gimson A., Jamieson N., Hudson M., Thick M., Heaton N., Mayer D., Neuberger J., Macgilchrist A., Forsythe J., Rolles K., Davies M., Pollard S., McCormick A., Traynor O., Truesdale A., Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. American Journal of Transplantation 2007 7 1 137 141 2-s2.0-33845600383 10.1111/j.1600-6143.2006.01576.x (Pubitemid 44952866)
72. Levy G., Grazi G. L., Sanjuan F., Wu Y., Mühlbacher F., Samuel D., Friman S., Jones R., Cantisani G., Villamil F., Cillo U., Clavien P. A., Klintmalm G., Otto G., Pollard S., McCormick P. A., Descalsi V., Gadano A., Villamil A., Angus P., Lynch S., Balderson G. A., Jeffreys G., Chester B., Steininger R., de Hemptinne B., Troisi R., Zanotelli M. L., Leonardi L., Boin I., Mies S., Guardia B. D., Lilly L., Marotta P., Wall W., Peltekian K., Roy A., Marleau D., Scudamore C., Yoshida M., Tchervenkov J., Cantarovich M., Boillot O., Bernard P., Calmus Y., Conti F., Cherqui D., Duvoux C., Ducerf C., Maar R., Gugenheim J., Myx A., Neau-Cransac D., Mouette K., Saliba F., Rostaing L., Kamar N., Moench C., O'Rourke M., D'Amico D., Varotti G., Maffei-Faccioli A., Gerunda G., Merenda R., Risaliti A., Baccarani U., Rossi M., Berloco P., Tanaka K., Oike F., Munn S., Gane E., Brekke I., Boberg K. M., Bernardos A., Garcia I., Cuervas V., Moreno J. M., Rimola A., Cirera I., Sanjuan F., Prieto M., Salcedo M., Clemente G., Ericson B., Gjertsen H., Herlenius G., Kadry Z., Mayer D., Hayes P., Davidson J., Hodgson J., Bynon J. S., Davis G., Ortiz J., Manzarbeita C., Mennon R., Weisner R. H., Wu Y., Chensu R. Y., Lake J. R., Humar A., 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplantation recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transplantation 2006 12 10 1464 1472 2-s2.0-33750112891 10.1002/lt.20802 (Pubitemid 44594275)
73. Berenguer M., Aguilera V., San Juan F., Benlloch S., Rubin A., López-Andujar R., Moya A., Pareja E., Montalva E., Yago M., de Juan M., Mir J., Prieto M., Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010 90 11 1204 1209 2-s2.0-78650307419 10.1097/TP.0b013e3181fa93fa
74. Berenguer M., Royuela A., Zamora J., Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transplantation 2007 13 1 21 29 2-s2.0-33846238124 10.1002/lt.21035 (Pubitemid 46099970)
75. Irish W. D., Arcona S., Bowers D., Trotter J. F., Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. American Journal of Transplantation 2011 11 8 1676 1685 2-s2.0-79961025286 10.1111/j.1600-6143.2011.03508.x
76. Berenguer M., Risk of extended criteria donors in hepatitis C virus-positive recipients. Liver Transplantation 2008 14 supplement 2 S45 S50 2-s2.0-58849098183
77. Nocito A., El-Badry A. M., Clavien P. A., When is steatosis too much for transplantation? Journal of Hepatology 2006 45 4 494 499 2-s2.0-33748104238 10.1016/j.jhep.2006.07.017 (Pubitemid 44307398)
78. Strasberg S. M., Howard T. K., Molmenti E. P., Hertl M., Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994 20 4, part 1 829 838 2-s2.0-0028059842 (Pubitemid 24296488)
79. Ploeg R. J., D'Alessandro A. M., Knechtle S. J., Stegall M. D., Pirsch J. D., Hoffmann R. M., Sasaki T., Sollinger H. W., Belzer F. O., Kalayoglu M., Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation 1993 55 4 807 813 2-s2.0-0027420075 (Pubitemid 23122053)
80. Feng S., Goodrich N. P., Bragg-Gresham J. L., Dykstra D. M., Punch J. D., DebRoy M. A., Greenstein S. M., Merion R. M., Characteristics associated with liver graft failure: the concept of a donor risk index. American Journal of Transplantation 2006 6 4 783 790 2-s2.0-33644747688 10.1111/j.1600-6143.2006. 01242.x (Pubitemid 43345017)
81. Briceño J., Ciria R., Pleguezuelo M., Naranjo A.., Sánchez-Hidalgo J., Ruiz-Rabelo J., López-Cillero P., Luque A., de la Mata M., Rufián S., Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplantation Proceedings 2007 39 7 2297 2299 2-s2.0-34548680741 10.1016/j.transproceed.2007.07.069 (Pubitemid 47418216)
82. Cameron A. M., Ghobrial R. M., Yersiz H., Farmer D. G., Lipshutz G. S., Gordon S. A., Zimmerman M., Hong J., Collins T. E., Gornbein J., Amersi F., Weaver M., Cao C., Chen T., Hiatt J. R., Busuttil R. W., Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Annals of Surgery 2006 243 6 748 753 2-s2.0-33745322911 10.1097/01.sla.0000219669.84192.b3
83. Hernandez-Alejandro R., Croome K. P., Quan D., Increased risk of severe recurrence of hepatitis C virus in liver transplant recipients of donation after cardiac death allografts. Transplantation 2011 92 6 686 689
84. Shiffman M. L., Stravitz R. T., Contos M. J., Mills A. S., Sterling R. K., Luketic V. A., Sanyal A. J., Cotterell A., Maluf D., Posner M. P., Fisher R. A., Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transplantation 2004 10 10 1248 1255 2-s2.0-6444236822 10.1002/lt.20232 (Pubitemid 39406078)
85. Humar A., Horn K., Kalis A., Glessing B., Payne W. D., Lake J., Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence? American Journal of Transplantation 2005 5 2 399 405 2-s2.0-13144258749 10.1111/j.1600-6143.2004. 00704.x (Pubitemid 40179528)
86. Maluf D. G., Stravitz R. T., Cotterell A. H., Posner M. P., Nakatsuka M., Sterling R. K., Luketic V. A., Shiffman M. L., Ham J. M., Marcos A., Behnke M. K., Fisher R. A., Adult living donor versus deceased donor liver transplantation: a 6-year single center experience. American Journal of Transplantation 2005 5 1 149 156 2-s2.0-19944428273 10.1111/j.1600-6143.2004. 00654.x (Pubitemid 40095140)
87. Russo M. W., Galanko J., Beavers K., Fried M. W., Shrestha R., Patient and graft surivival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transplantation 2004 10 3 340 346 2-s2.0-1642286845 10.1002/lt.20090 (Pubitemid 38380305)
88. Bozorgzadeh A., Jain A., Ryan C., Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. Transplantation 2004 77 7 12 1066 1070 (Pubitemid 38508925)
89. van Vlierberghe H., Troisi R., Colle I., Ricciardi S., Praet M., de Hemptinne B., Hepatitis C infection-related liver disease: patterns of recurrence and outcome in cadaveric and living-donor liver transplantation in adults. Transplantation 2004 77 2 210 214 2-s2.0-0742304549 10.1097/01.TP. 0000101007.59478.8B (Pubitemid 38155748)
90. Schiano T. D., Gutierrez J. A., Walewski J. L., Fiel M. I., Cheng B., Bodenheimer H., Thung S. N., Chung R. T., Schwartz M. E., Bodian C., Branch A. D., Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology 2005 42 6 1420 1428 2-s2.0-32944465950 10.1002/hep.20947 (Pubitemid 43260046)
91. Guo L., Orrego M., Rodriguez-Luna H., Balan V., Byrne T., Chopra K., Douglas D. D., Harrison E., Moss A., Reddy K. S., Williams J. W., Rakela J., Mulligan D., Vargas H. E., Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transplantation 2006 12 4 560 565 2-s2.0-33645552627 10.1002/lt.20660
92. Terrault N. A., Shiffman M. L., Lok A. S. F., Saab S., Tong L., Brown R. S., Everson G. T., Reddy K. R., Fair J. H., Kulik L. M., Pruett T. L., Seeff L. B., Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transplantation 2007 13 1 122 129 2-s2.0-33846232683 10.1002/lt.20995 (Pubitemid 46099981)
93. Schmeding M., Neumann U. P., Puhl G., Bahra M., Neuhaus R., Neuhaus P., Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transplantation 2007 13 5 687 692 2-s2.0-34249077865 10.1002/lt.21138 (Pubitemid 46796540)
94. Selzner N., Girgrah N., Lilly L., Guindi M., Selzner M., Therapondos G., Adeyi O., McGilvray I., Cattral M., Greig P. D., Grant D., Levy G., Renner E. L., The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. Liver Transplantation 2008 14 12 1778 1786 2-s2.0-58249093025 10.1002/lt.21598
95. Jain A., Singhal A., Kashyap R., Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up. Transplantation 2011 92 4 453 460
96. Charlton M., Seaberg E., Wiesner R., Everhart J., Zetterman R., Lake J., Detre K., Hoofnagle J., Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998 28 3 823 830 2-s2.0-0031783001 (Pubitemid 28405436)
97. McCaughan G. W., Zekry A., Mechanisms of HCV reinfection and allograft damage after liver transplantation. Journal of Hepatology 2004 40 3 368 374 2-s2.0-1242269878 10.1016/j.jhep.2004.01.014 (Pubitemid 38230834)
98. Firpi R. J., Abdelmalek M. F., Soldevila-Pico C., Cabrera R., Shuster J. J., Theriaque D., Reed A. I., Hemming A. W., Liu C., Crawford J. M., Nelson D. R., One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transplantation 2004 10 10 1240 1247 2-s2.0-6444236097 10.1002/lt.20238 (Pubitemid 39406077)
99. Moeller M., Zalawadia A., Alrayes A., Divine G., Brown K., Moonka D., The impact of donor race on recurrent hepatitis C after liver transplantation. Transplantation Proceedings 2010 42 10 4175 4177 2-s2.0-78650503077 10.1016/j.transproceed.2010.09.079
100. Sugawara Y., Tamura S., Kokudo N., Liver transplantation in HCV/HIV positive patients. World Journal of Gastrointestinal Surgery 2011 3 2 21 28
101. Duclos-Vallee J. C., Feray C., Sebagh M., Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008 47 2 407 417 (Pubitemid 351280708)
102. Duclos-Vallee J. C., Falissard B., Samuel D., Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with a synthetic cohort. AIDS 2011 25 13 1675 1676
103. Moreno A., Cervera C., Fortun J., Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transplantation 2012 18 1 70 81
104. de Vera M. E., Dvorchik I., Tom K., Eghtesad B., Thai N., Shakil O., Marcos A., Demetris A., Jain A., Fung J. J., Ragni M. V., Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by
105. Fung J., Eghtesad B., Patel-Tom K., DeVera M., Chapman H., Ragni M., Liver transplantation in patients with HIV infection. Liver Transplantation 2004 10 10, supplement 2 S39 S53 2-s2.0-6444224860 (Pubitemid 39406100)
106. Wojcik K., Vogel M., Voigt E., Speidel N., Kalff J. C., Goldmann G., Oldenburg J., Sauerbruch T., Rockstroh J. K., Spengler U., Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort. AIDS 2007 21 10 1363 1365 2-s2.0-34250013077 10.1097/QAD.0b013e3280d5a79a (Pubitemid 46883493)
107. Kemmer N. M., Sherman K. E., Liver transplantation trends in the HIV population. Digestive Diseases and Sciences 2011 56 11 3393 3398
108. Fukuhara T., Taketomi A., Motomura T., Okano S., Ninomiya A., Abe T., Uchiyama H., Soejima Y., Shirabe K., Matsuura Y., Maehara Y., Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010 139 5, article e3 1577 1585 2-s2.0-78049470128 10.1053/j.gastro.2010.07.058
109. Eurich D., Boas-Knoop S., Ruehl M., Schulz M., Carrillo E. D., Berg T., Neuhaus R., Neuhaus P., Neumann U. P., Bahra M., Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transplantation 2011 17 3 289 298 2-s2.0-79952417218 10.1002/lt.22235
110. Lange C. M., Moradpour D., Doehring A., Lehr H. A., Müllhaupt B., Bibert S., Bochud P. Y., Antonino A. T., Pascual M., Farnik H., Shi Y., Bechstein W. O., Moench C., Hansmann M. L., Sarrazin C., Lötsch J., Zeuzem S., Hofmann W. P., Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. Journal of Hepatology 2011 55 2 322 327 2-s2.0-79960452181 10.1016/j.jhep.2010.10.037
111. Coto-Llerena M., Crespo G., Gonzalez P., Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. Journal of Hepatology 2012 56 2 355 358 10.1016/j.jhep.2011.07.027
112. Rosen H. R., Chou S., Corless C. L., Gretch D. R., Flora K. D., Boudousquie A., Orloff S. L., Rabkin J. M., Benner K. G., Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997 64 5 721 726 2-s2.0-0030985417 10.1097/00007890-199709150-00010 (Pubitemid 27407099)
113. Humara A., Kumar D., Raboud J., Caliendod A. M., Moussa G., Levya G., Mazzulli T., Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. American Journal of Transplantation 2002 2 5 461 466 2-s2.0-0036589963 10.1034/j.1600-6143.2002. 20511.x (Pubitemid 36306888)
114. Teixeira R., Pastacaldi S., Davies S., Dhillon A. P., Emery V. C., Rolles K., Davidson B., Patch D., Burroughs A. K., The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation. Transplantation 2000 70 10 1454 1458 2-s2.0-0034722635
115. Nebbia G., Mattes F. M., Cholongitas E., Garcia-Diaz A., Samonakis D. N., Burroughs A. K., Emery V. C., Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transplantation 2007 13 1 130 135 2-s2.0-33846245968 10.1002/lt.21037 (Pubitemid 46099982)
116. Humar A., Washburn K., Freeman R., Paya C. V., Mouas H., Alecock E., Razonable R. R., An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transplantation 2007 13 10 1422 1427 2-s2.0-35448937998 10.1002/lt.21266 (Pubitemid 47629576)
117. Baid S., Cosimi A. B., Lin Farrell M., Schoenfeld D. A., Feng S., Chung R. T., Tolkoff-Rubin N., Pascual M., Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal, relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001 72 6 1066 1072 2-s2.0-0035960038 (Pubitemid 32924079)
118. Foxton M. R., Quaglia A., Muiesan R., Heneghan M. A., Portmann B., Norris S., Heaton N. D., O'Grady J. G., The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. American Journal of Transplantation 2006 6 8 1922 1929 2-s2.0-33745779889 10.1111/j.1600-6143.2006. 01408.x (Pubitemid 44024965)
119. AlDosary A. A., Ramji A. S., Elliott T. G., Sirrs S. M., Thompson D. M., Erb S. R., Steinbrecher U. P., Yoshida E. M., Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transplantation 2002 8 4 356 361 2-s2.0-0036245119 10.1053/jlts.2002.31745 (Pubitemid 34467370)
120. Gane E. J., Diabetes mellitus following liver transplantation in patients with hepatitis C virus: risks and consequences. American Journal of Transplantation 2012 12 3 531 538 10.1111/j.1600-6143.2011.03854.x
121. Veldt B. J., Poterucha J. J., Watt K. D. S., Wiesner R. H., Hay J. E., Rosen C. B., Heimbach J. K., Janssen H. L. A., Charlton M. R., Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. American Journal of Transplantation 2009 9 6 1406 1413 2-s2.0-66249095118 10.1111/j.1600-6143.2009.02642.x
122. Samonakis D. N., Triantos C. K., Thalheimer U., Quaglia A., Leandro G., Teixeira R., Papatheodoridis G. V., Sabin C. A., Rolando N., Davies S., Dhillon A. P., Griffiths P., Emery V., Patch D. W., Davidson B. R., Rolles K., Burroughs A. K., Immunosuppresion and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transplantation 2005 11 4 386 395 2-s2.0-20244366386 10.1002/lt.20344 (Pubitemid 40533206)
123. Charlton M., Seaberg E., Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the national institute of diabetes and digestive and kidney diseases liver transplantation database. Liver Transplantation and Surgery 1999 5 4, supplement 1 S107 S114 2-s2.0-0033028424 (Pubitemid 29321242)
124. Neumann U. P., Berg T., Bahra M., Puhl G., Guckelberger L., Langrehr J. M., Neuhaus P., Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004 77 2 226 231 2-s2.0-0742321955 10.1097/01.TP.0000101738.27552.9D (Pubitemid 38155751)
125. Eason J. D., Nair S., Cohen A. J., Blazek J. L., Loss G. E., Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003 75 8 1396 1399 2-s2.0-0037469018 10.1097/01.TP.0000062834.30922.FE (Pubitemid 36513055)
126. Filipponi F., Callea F., Salizzoni M., Grazi G. L., Fassati L. R., Rossi M., Risaliti A., Burra P., Agnes S., de Carlis L., Valente U., Ferrara R., Pisati R., Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab+steroids or basiliximab+placebo, in addition to cyclosporine and azathioprine. Transplantation 2004 78 10 1488 1495 2-s2.0-9244243058 10.1097/01.TP.0000140881. 07208.4E (Pubitemid 39552935)
127. Segev D. L., Sozio S. M., Shin E. J., Nazarian S. M., Nathan H., Thuluvath P. J., Montgomery R. A., Cameron A. M., Maley W. R., Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transplantation 2008 14 4 512 525 2-s2.0-42149168448 10.1002/lt.21396 (Pubitemid 351524408)
128. Calmus Y., Scheele J. R., Gonzalez-Pinto I., Jaurrieta E. J., Klar E., Pageaux G. P., Scudamore C. H., Cuervas-Mons V., Metselaar H. J., Prestele H., Girault D., Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transplantation 2002 8 2 123 131 2-s2.0-0036193103 10.1053/jlts.2002.30882 (Pubitemid 34202140)
129. Klintmalm G. B. G., Washburn W. K., Rudich S. M., Heffron T. G., Teperman L. W., Fasola C., Eckhoff D. E., Netto G. J., Katz E., Corticosteroid-free immunosuppression with daclizumab in HCV+ liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transplantation 2007 13 11 1521 1531 2-s2.0-36448976921 10.1002/lt.21182 (Pubitemid 350168192)
130. Neuhaus P., Clavien P. A., Kittur D., Salizzoni M., Rimola A., Abeywickrama K., Ortmann E., Chodoff L., Hall M., Korn A., Nashan B., Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transplantation 2002 8 2 132 142 2-s2.0-0036192366 10.1053/jlts.2002.30302 (Pubitemid 34202141)
131. Nelson D. R., Soldevila-Pico C., Reed A., Abdelmalek M. F., Hemming A. W., van der Werf W. J., Howard R., Davis G. L., Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transplantation 2001 7 12 1064 1070 2-s2.0-0035666292 10.1053/jlts.2001.29414 (Pubitemid 34023993)
132. Jain A., Kashyap R., Demetris A. J., Eghstesad B., Pokharna R., Fung J. J., A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transplantation 2002 8 1 40 46 2-s2.0-0036149695 10.1053/jlts.2002.29763 (Pubitemid 34092671)
133. Wiesner R. H., Shorr J. S., Steffen B. J., Chu A. H., Gordon R. D., Lake J. R., Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transplantation 2005 11 7 750 759 2-s2.0-22144442065 10.1002/lt.20453 (Pubitemid 40975576)
134. Sánchez-Bueno F., Ortiz M. L., Bermejo J., Miras M., Pons J. A., Ramírez P., Robles R., Parrilla P., Prognostic factors for hepatitis C recurrence in patients undergoing orthotopic liver transplantation. Transplant Immunology 2006 17 1 47 50 2-s2.0-33751506972 10.1016/j.trim.2006.09.029 (Pubitemid 44834655)
135. Manzia T. M., Angelico R., Toti L., Bellini M. I., Sforza D., Palmieri G., Orlando G., Tariciotti L., Angelico M., Tisone G., Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. Transplant International 2011 24 5 461 468 2-s2.0-79953768508 10.1111/j.1432-2277.2011.01228.x
136. Kornberg A., Küpper B., Wilberg J., Tannapfel A., Thrum K., Bärthel E., Hommann M., Settmacher U., Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients. Transplant Infectious Disease 2007 9 4 295 301 2-s2.0-35848963850 10.1111/j.1399-3062.2007. 00228.x (Pubitemid 350059145)
137. Kornberg A., Küpper B., Tannapfel A., Hommann M., Scheele J., Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation. International Immunopharmacology 2005 5 1 107 115 2-s2.0-10344243982 10.1016/j.intimp.2004.09.010 (Pubitemid 39626692)
138. Bahra M., Neumann U. I. F. P., Jacob D., Puhl G., Klupp J., Langrehr J. M., Berg T., Neuhaus P., MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. American Journal of Transplantation 2005 5 2 406 411 2-s2.0-13144252194 10.1111/j.1600-6143.2004. 00706.x (Pubitemid 40179529)
139. Zekry A., Gleeson M., Guney S., McCaughan G. W., A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transplantation 2004 10 1 52 57 2-s2.0-3042771789 10.1002/lt.20000 (Pubitemid 38885893)
140. Germani G., Pleguezuelo M., Villamil F., Vaghjiani S., Tsochatzis E., Andreana L., Burroughs A. K., Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. American Journal of Transplantation 2009 9 8 1725 1731 2-s2.0-67650938464 10.1111/j.1600-6143.2009.02705.x
141. Kawahara T., Asthana S., Kneteman N. M., m-TOR inhibitors: what role in liver transplantation? Journal of Hepatology 2011 55 6 1441 1451 10.1016/j.jhep.2011.06.01
142. Asthana S., Toso C., Meeberg G., The impact of sirolimus on hepatitis C recurrence after liver transplantation. Canadian Journal of Gastroenterology 2011 25 1 28 34
143. Harper S. J. F., Gelson W., Harper I. G., Alexander G. J. M., Gibbs P., Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: a single-center experience. Transplantation 2011 91 1 128 132 2-s2.0-78751644737 10.1097/TP.0b013e3181fe131b
144. Gaglio P. J., Malireddy S., Levitt B. S., Lapointe-Rudow D., Lefkowitch J., Kinkhabwala M., Russo M. W., Emond J. C., Brown R. S., Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transplantation 2003 9 10 1028 1035 2-s2.0-0142248361 10.1053/jlts.2003.50211 (Pubitemid 37304457)
145. Garcia-Retortillo M., Forns X., Llovet J. M., Navasa M., Feliu A., Massaguer A., Bruguera M., Fuster J., Garcia-Valdecasas J. C., Rimola A., Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004 40 3 699 707 2-s2.0-4544346219 10.1002/hep.20357 (Pubitemid 39265593)
146. Thuluvath P. J., Yoo H. Y., Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation. Liver Transplantation 2004 10 10 1263 1268 2-s2.0-6444232241 10.1002/lt.20254 (Pubitemid 39406081)
147. Fausto N., Campbell J. S., The role of hepatocytes and oval cells in liver regeneration and repopulation. Mechanisms of Development 2003 120 1 117 130 2-s2.0-0037213389 10.1016/S0925-4773(02)00338-6 (Pubitemid 35462100)
148. Zimmerman M. A., Trotter J. F., Living donor liver transplantation in patients with hepatitis C. Liver Transplantation 2003 9 11 S52 S57 2-s2.0-0242539726 10.1053/jlts.2003.50256 (Pubitemid 37408004)
149. Olthoff K. M., Hepatic regeneration in living donor liver transplantation. Liver Transplantation 2003 9 10, supplement 2 S35 S41 2-s2.0-0142155141 (Pubitemid 37304445)
150. Everson G. T., Trotter J., Role of adult living donor liver transplantation in patients with hepatitis C. Liver Transplantation 2003 9 10, supplement 2 S64 S68 2-s2.0-0142155146 (Pubitemid 37304451)
151. Manez R., Mateo R., Tabasco J., Kusne S., Starzl T. E., Duquesnoy R. J., The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation. Transplantation 1995 59 4 640 642 2-s2.0-0028910297
152. Roche B., Samuel D., Hepatitis C virus treatment pre- and post-liver transplantation. Liver International 2012 32 supplement 1 120 128 10.1111/j.1478-3231.2011.02714.x
153. Carrión J. A., Martínez-Bauer E., Crespo G., Ramírez S., Pérez-del-Pulgar S., García-Valdecasas J. C., Navasa M., Forns X., Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. Journal of Hepatology 2009 50 4 719 728 2-s2.0-61749085030 10.1016/j.jhep.2008.11.015
154. Forns X., García-Retortillo M., Serrano T., Feliu A., Suarez F., de La Mata M., García-Valdecasas J. C., Navasa M., Rimola A., Rodés J., Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. Journal of Hepatology 2003 39 3 389 396 2-s2.0-10744234013 10.1016/S0168-8278(03)00310-6 (Pubitemid 37070256)
155. Crippin J. S., McCashland T., Terrault N., Sheiner P., Charlton M. R., A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transplantation 2002 8 4 350 355 2-s2.0-0036245493 10.1053/jlts.2002.31748 (Pubitemid 34467369)
156. Everson G. T., Trotter J., Forman L., Kugelmas M., Halprin A., Fey B., Ray C., Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005 42 2 255 262 2-s2.0-23044500773 10.1002/hep.20793 (Pubitemid 41061075)
157. Thomas R. M., Brems J. J., Guzman-Hartman G., Yong S., Cavaliere P., van Thiel D. H., Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transplantation 2003 9 9 905 915 2-s2.0-0042882410 10.1053/jlts.2003.50166 (Pubitemid 37098838)
158. Everson G. T., Terrault N. A., Lok A. S., A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 10.1002/hep.25976
159. Shergill A. K., Khalili M., Straley S., Bollinger K., Roberts J. P., Ascher N. A., Terrault N. A., Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. American Journal of Transplantation 2005 5 1 118 124 2-s2.0-11844249361 10.1111/j.1600-6143.2004.00648.x (Pubitemid 40095135)
160. Mazzaferro V., Tagger A., Schiavo M., Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplantation Proceedings 2001 33 1-2 1355 1357 2-s2.0-0035077063 10.1016/S0041-1345(00)02508-2 (Pubitemid 32237879)
161. Tamura S., Sugawara Y., Yamashiki N., Kaneko J., Kokudo N., Makuuchi M., Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience. Transplant International 2010 23 6 580 588 2-s2.0-77951944714 10.1111/j.1432-2277.2009. 01023.x
162. Kuo A., Tan V., Lan B., Khalili M., Feng S., Roberts J. P., Terrault N. A., Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transplantation 2008 14 10 1491 1497 2-s2.0-57849162852 10.1002/lt.21548
163. Chalasani N., Manzarbeitia C., Ferenci P., Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005 41 2 289 298 (Pubitemid 40165372)
164. Singh N., Gayowski T., Wannstedt C. F., Shakil A. O., Wagener M. M., Fung J. J., Marino I. R., Interferon- for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998 65 1 82 86 2-s2.0-0031887327 10.1097/00007890-199801150- 00016 (Pubitemid 28100436)
165. Bzowej N., Nelson D. R., Terrault N. A., Everson G. T., Teng L. L., Prabhakar A., Charlton M. R., PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transplantation 2011 17 5 528 538 2-s2.0-79955060448 10.1002/lt.22271
166. Roche B., Sebagh M., Canfora M. L., Antonini T., Roque-Afonso A. M., delvart V., Saliba F., Duclos-Vallee J. C., Castaing D., Samuel D., Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transplantation 2008 14 12 1766 1777 2-s2.0-58249086156 10.1002/lt.21635
167. Berenguer M., Aguilera V., Prieto M., Ortiz C., Rodríguez M., Gentili F., Risalde B., Rubin A., Cañada R., Palau A., Rayón J. M., Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transplantation 2009 15 7 738 746 2-s2.0-68349154245 10.1002/lt.21707
168. Rodriguez-Luna H., Khatib A., Sharma P., de Petris G., Williams J. W., Ortiz J., Hansen K., Mulligan D., Moss A., Douglas D. D., Balan V., Rakela J., Vargas H. E., Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon 2b and ribavirin: an open-label series. Transplantation 2004 77 2 190 194 2-s2.0-10744233319 10.1097/01.TP.0000100481.14514.BB (Pubitemid 38155744)
169. Neff G. W., Montalbano M., O'Brien C. B., Nishida S., Safdar K., Bejarano P. A., Khaled A. S., Ruiz P., Slapak-Green G., Lee M., Nery J., de Medina M., Tzakis A., Schiff E. R., Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004 78 9 1303 1307 2-s2.0-8644285360 10.1097/01.TP.0000129811.93072.1C (Pubitemid 39507968)
170. Ross A. S., Bhan A. K., Pascual M., Thiim M., Cosimi A. B., Chung R. T., Pegylated interferon -2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clinical Transplantation 2004 18 2 166 173 2-s2.0-1642565346 10.1046/j.1399-0012.2003.00145.x (Pubitemid 38404647)
171. Babatin M., Schindel L., Burak K. W., Pegylated-interferon alpha 2b and ribavirin for recurrent hepatities C after liver liver transplantation: from a Canadian experience to recommendations for therapy. Canadian Journal of Gastroenterology 2005 19 6 359 365 2-s2.0-22444439336 (Pubitemid 41007495)
172. Castells L., Vargas V., Allende H., Bilbao I., Lázaro J. L., Margarit C., Esteban R., Guardia J., Combined treatment with pegylated interferon (-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. Journal of Hepatology 2005 43 1 53 59 2-s2.0-20444377637 10.1016/j.jhep.2005.02.015 (Pubitemid 40805272)
173. Toniutto P., Fabris C., Fumo E., Apollonio L., Caldato M., Avellini C., Minisini R., Pirisi M., Pegylated versus standard interferon- in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy. Journal of Gastroenterology and Hepatology 2005 20 4 577 582 2-s2.0-19944386924 10.1111/j.1440-1746.2005.03795.x (Pubitemid 40755270)
174. Berenguer M., Palau A., Fernandez A., Benlloch S., Aguilera V., Prieto M., Rayón J. M., Berenguer J., Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transplantation 2006 12 7 1067 1076 2-s2.0-33745997054 10.1002/lt.20737 (Pubitemid 44063780)
175. Biselli M., Andreone P., Gramenzi A., Lorenzini S., Loggi E., Bonvicini F., Cursaro C., Bernardi M., Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen. Digestive and Liver Disease 2006 38 1 27 32 2-s2.0-33646815725 10.1016/j.dld.2005.08.009 (Pubitemid 44356137)
176. Fernández I., Meneu J. C., Colina F., García I., Muñoz R., Castellano G., Fuertes A., Abradelo M., Lumbreras C., Moreno E., Solís-Herruzo J. A., Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transplantation 2006 12 12 1805 1812 2-s2.0-33845488548 10.1002/lt.20883 (Pubitemid 44911807)
177. Mukherjee S., Lyden E., Impact of pegylated interferon -2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Liver International 2006 26 5 529 535 2-s2.0-33646813936 10.1111/j.1478-3231.2006.01261.x
178. Neumann U., Puhl G., Bahra M., Berg T., Langrehr J. M., Neuhaus R., Neuhaus P., Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006 82 1 43 47 2-s2.0-33747519995 10.1097/01.tp.0000225827.18034.be (Pubitemid 44296976)
179. Oton E., Barcena R., Moreno-Planas J. M., Cuervas-Mons V., Moreno-Zamora A., Barrios C., Garcia-Garzon S., Moreno A., Boullosa-Graña E., Rubio-Gonzalez E. E., Garcia-Gonzalez M., Blesa C., Mateos M. L., Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg-interferon and ribavirin. American Journal of Transplantation 2006 6 10 2348 2355 2-s2.0-33748497126 10.1111/j.1600-6143.2006.01470.x (Pubitemid 44359420)
180. Angelico M., Petrolati A., Lionetti R., Lenci I., Burra P., Donato M. F., Merli M., Strazzabosco M., Tisone G., A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. Journal of Hepatology 2007 46 6 1009 1017 2-s2.0-34247605934 10.1016/j.jhep.2006.12.017 (Pubitemid 46680357)
181. Carrión J. A., Navasa M., García-Retortillo M., García-Pagan J. C., Crespo G., Bruguera M., Bosch J., Forns X., Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007 132 5 1746 1756 2-s2.0-34247863801 10.1053/j.gastro.2007.03.041 (Pubitemid 46695723)
182. Picciotto F. P., Tritto G., Lanza A. G., Addario L., de Luca M., Di Costanzo G., Lampasi F., Tartaglione M. T., Marsilia G. M., Calise F., Cuomo O., Ascione A., Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. Journal of Hepatology 2007 46 3 459 465 2-s2.0-33846589289 10.1016/j.jhep.2006.10.017 (Pubitemid 46185706)
183. Sharma P., Marrero J. A., Fontana R. J., Greenson J. K., Conjeevaram H., Su G. L., Askari F., Sullivan P., Lok A. S., Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transplantation 2007 13 8 1100 1108 2-s2.0-34250866552 10.1002/lt.21121 (Pubitemid 47305028)
184. Zimmermann T., Böcher W. O., Biesterfeld S., Zimmermann A., Kanzler S., Greif-Higer G., Barreiros A. P., Sprinzl M. F., Wörns M. A., Lohse A. W., Mönch C., Otto G., Galle P. R., Schuchmann M., Efficacy of an escalating dose regimen of pegylated interferon -2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transplant International 2007 20 7 583 590 2-s2.0-34249897781 10.1111/j.1432-2277.2007.00481.x (Pubitemid 46872748)
185. Hanouneh I. A., Miller C., Aucejo F. N., Lopez R., Quinn M. K., Zein N. N., Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transplantation 2008 14 1 53 58 2-s2.0-38649139137 10.1002/lt.21312 (Pubitemid 351167989)
186. Lodato F., Berardi S., Gramenzi A., Mazzella G., Lenzi M., Morelli M. C., Tame M. R., Piscaglia F., Andreone P., Ballardini G., Bernardi M., Bianchi F. B., Biselli M., Bolondi L., Cescon M., Colecchia A., D'Errico A., del Gaudio M., Ercolani G., Grazi G. L., Grigioni W., Lorenzini S., Pinna A. D., Ravaioli M., Roda E., Sama C., Vivarelli M., Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Alimentary Pharmacology and Therapeutics 2008 28 4 450 457 2-s2.0-47749146522 10.1111/j.1365-2036.2008.03761.x (Pubitemid 352033285)
187. Dinges S., Morard I., Heim M., Dufour J. F., Müllhaupt B., Giostra E., Clavien P. A., Mentha G., Negro F., Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. Transplant Infectious Disease 2009 11 1 33 39 2-s2.0-58649094870 10.1111/j.1399-3062.2008. 00359.x
188. Jain A., Sharma R., Ryan C., Safadjou S., Kashyap R., Mantry P., Maliakkal B., Orloff M., Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience. Clinical Transplantation 2010 24 1 104 111 2-s2.0-74949083503 10.1111/j.1399-0012.2009.00961.x
189. Schmidt S. C., Bahra M., Bayraktar S., Berg T., Schmeding M., Pratschke J., Neuhaus P., Neumann U., Antiviral treatment of patients with recurrent hepatitis c after liver transplantation with pegylated interferon. Digestive Diseases and Sciences 2010 55 7 2063 2069 2-s2.0-77954427473 10.1007/s10620-009-0982-2
190. Al-Hamoudi W., Mohamed H., Abaalkhail F., Kamel Y., Al-Masri N., Allam N., Alqahtani S., Al-Sofayan M., Khalaf H., Al-Sebayel M., Al-Jedai A., Abdo A., Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin. Digestive Diseases and Sciences 2011 56 6 1848 1852 2-s2.0-79959750829 10.1007/s10620-010-1526-5
191. Gurusamy K. S., Tsochatzis E., Davidson B. R., Burroughs A. K., Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database of Systematic Reviews 2010 12 CD006573 2-s2.0-79952201112
192. Veldt B. J., Poterucha J. J., Watt K. D. S., Wiesner R. H., Hay J. E., Kremers W. K., Rosen C. B., Heimbach J. K., Charlton M. R., Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. American Journal of Transplantation 2008 8 11 2426 2433 2-s2.0-53749103476 10.1111/j.1600-6143.2008. 02362.x
193. Berenguer M., Palau A., Aguilera V., Rayón J. M., Juan F. S., Prieto M., Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. American Journal of Transplantation 2008 8 3 679 687 2-s2.0-39649100163 10.1111/j.1600-6143.2007.02126.x (Pubitemid 351287553)
194. Firpi R. J., Clark V., Soldevila-Pico C., Morelli G., Cabrera R., Levy C., Machicao V. I., Chaoru C., Nelson D. R., The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transplantation 2009 15 9 1063 1071 2-s2.0-70350524724 10.1002/lt.21784
195. McCashland T., Watt K., Lyden E., Adams L., Charlton M., Smith A. D., McGuire B. M., Biggins S. W., Neff G., Burton J. R., Vargas H., Donovan J., Trotter J., Faust T., Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transplantation 2007 13 9 1246 1253 2-s2.0-34648822902 10.1002/lt.21322 (Pubitemid 47457051)
196. Martí J., Charco R., Ferrer J., Calatayud D., Rimola A., Navasa M., Fondevila C., Fuster J., García-Valdecasas J. C., Optimization of liver grafts in liver retransplantation: a European single-center experience. Surgery 2008 144 5 762 769 2-s2.0-54049117125 10.1016/j.surg.2008.06.029
197. Sugawara Y., Makuuchi M., Matsui Y., Kishi Y., Akamatsu N., Kaneko J., Kokudo N., Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004 78 9 1308 1311 2-s2.0-8644222054 10.1097/01.TP.0000142677.12473.E5 (Pubitemid 39507969)
198. Kishi Y., Sugawara Y., Akamatsu N., Kaneko J., Tamura S., Kokudo N., Makuuchi M., Splenectomy and preemptive interferon therapy for hepatitis C patients after living-donor liver transplantation. Clinical Transplantation 2005 19 6 769 772 2-s2.0-28644433371 10.1111/j.1399-0012.2005.00419.x (Pubitemid 41748730)
199. Tamura S., Sugawara Y., Yamashiki N., Kaneko J., Kokudo N., Makuuchi M., Preemptive antiviral treatment for hepatitis C virus after living donor liver transplantation. Transplantation Proceedings 2012 44 3 971 973 10.1016/j.transproceed.2012.01.031
200. Ueda Y., Takada Y., Haga H., Nabeshima M., Marusawa H., Ito T., Egawa H., Tanaka K., Uemoto S., Chiba T., Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation. Transplantation 2008 85 6 855 862 2-s2.0-41149123529 10.1097/TP.0b013e3181671df0 (Pubitemid 351440751)
201. Ueda Y., Takada Y., Marusawa H., Egawa H., Uemoto S., Chiba T., Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation. Transplantation 2010 90 6 661 665 2-s2.0-77957252221 10.1097/TP.0b013e3181d2bfca
202. Ueda Y., Marusawa H., Kaido T., Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation. Journal of Viral Hepatitis 2012 19 1 32 38
203. Ikegami T., Taketomi A., Soejima Y., Yoshizumi T., Fukuhara T., Kotoh K., Shimoda S., Kato M., Maehara Y., The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C. Transplantation Proceedings 2009 41 10 4246 4252 2-s2.0-71249097940 10.1016/j.transproceed.2009.08.070
204. Eguchi S., Takatsuki M., Soyama A., Hidaka M., Tokai H., Hamasaki K., Miyazaki K., Tajima Y., Ichikawa T., Kanematsu T., Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation. Annals of Transplantation 2007 12 4 11 15 2-s2.0-46749144672
205. Kawaoka T., Hiraga N., Takahashi S., Takaki S., Mitsui F., Tsuge M., Nagaoki Y., Kimura Y., Hashimoto Y., Katamura Y., Hiramatsu A., Waki K., Imamura M., Kawakami Y., Aikata H., Tashiro H., Ohdan H., Chayama K., Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus. Scandinavian Journal of Gastroenterology 2010 45 12 1488 1496 2-s2.0-78649300371 10.3109/00365521.2010.505657
206. Masuda Y., Nakazawa Y., Matsuda K., Sano K., Mita A., Ohno Y., Urata K., Ikegami T., Miwa S., Miyagawa S., Clinicopathological features of hepatitis C virus disease after living donor liver transplantation: relationship with in situ hybridisation data. Pathology 2011 43 2 156 160 2-s2.0-79955969217 10.1097/PAT.0b013e32834317ed
207. Marubashi S., Dono K., Nagano H., Kim C., Asaoka T., Hama N., Kobayashi S., Takeda Y., Umeshita K., Monden M., Doki Y., Mori M., Steroid-free living donor liver transplantation in adults: impact on hepatitis C recurrence. Clinical Transplantation 2009 23 6 904 913 2-s2.0-71149099685 10.1111/j.1399-0012.2009.01022.x
208. Jeng L. B., Lee C. C., Chiang H. C., Chen T. H., Hsu C. H., Cheng H. T., Lai H. C., Indication for splenectomy in the Era of living-donor liver transplantation. Transplantation Proceedings 2008 40 8 2531 2533 2-s2.0-53149088201 10.1016/j.transproceed.2008.07.016
209. Yoshizumi T., Taketomi A., Soejima Y., Ikegami T., Uchiyama H., Kayashima H., Harada N., Yamashita Y. I., Kawanaka H., Nishizak T., Maehara Y., The beneficial role of simultaneous splenectomy in living donor liver transplantation in patients with small-for-size graft. Transplant International